array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2432)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(45) "Odronextamab in diffuse large B-cell lymphoma"
["snippet_en"]=>
string(82) "Odronextamab data from the pivotal study in relapsed/refractory diffuse large cell"
["url"]=>
string(78) "https://arznei-news.de/odronextamab-bei-diffusem-grosszelligen-b-zell-lymphom/"
["image_url"]=>
NULL
["source"]=>
string(14) "arznei-news.de"
["publication_date"]=>
string(10) "2023-12-10"
["categories"]=>
array(2) {
[0]=>
string(13) "Data Security"
[1]=>
string(17) "Academic Research"
}
}
[1]=>
array(7) {
["title_en"]=>
string(97) "Regeneron and Sanofi advance Dupixent program after FDA seeks more efficacy data By Investing.com"
["snippet_en"]=>
string(80) "Regeneron and Sanofi advance Dupixent program after FDA seeks more efficacy data"
["url"]=>
string(142) "https://www.investing.com/news/stock-market-news/regeneron-and-sanofi-advance-dupixent-program-after-fda-seeks-more-efficacy-data-93CH-3206089"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-10-23"
["categories"]=>
array(1) {
[0]=>
string(13) "Data Security"
}
}
[2]=>
array(7) {
["title_en"]=>
string(67) "Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO"
["snippet_en"]=>
string(157) "Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy."
["url"]=>
string(120) "https://scrip.pharmaintelligence.informa.com/SC148506/Regeneron-Pfizer-Tout-Potential-BCMA-Bispecific-Advantages-At-ASCO"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d61b4579-f09b-4c87-8742-8898a480fccf"
["source"]=>
string(11) "informa.com"
["publication_date"]=>
string(10) "2023-06-06"
["categories"]=>
array(2) {
[0]=>
string(13) "Data Security"
[1]=>
string(10) "Cybercrime"
}
}
[3]=>
array(7) {
["title_en"]=>
string(63) "Regeneron reveals data behind deprioritized BCMA/CD3 bispecific"
["snippet_en"]=>
string(173) "ORLANDO – Regeneron on Monday revealed the data behind one of its BCMA and CD3-directed bispecific antibodies that it has decided not to take forward for multiple myeloma."
["url"]=>
string(83) "https://endpts.com/regeneron-reveals-data-behind-deprioritized-bcma-cd3-bispecific/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/562c8896-de64-4c3f-84b2-ed4baa1662b7"
["source"]=>
string(10) "endpts.com"
["publication_date"]=>
string(10) "2023-04-17"
["categories"]=>
array(3) {
[0]=>
string(13) "Data Security"
[1]=>
string(10) "Cybercrime"
[2]=>
string(16) "Customer Privacy"
}
}
[4]=>
array(7) {
["title_en"]=>
string(70) "StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron"
["snippet_en"]=>
string(139) "Regeneron Pharmaceuticals shares rose 10% following positive Phase III data for Dupixent® in chronic obstructive pulmonary disease (COPD)."
["url"]=>
string(114) "https://www.genengnews.com/lung-diseases/copd/stockwatch-copd-data-analysts-treg-cell-therapy-deal-lift-regeneron/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/e877a4b1-2dc4-4b47-bd16-859f5e7cb44f"
["source"]=>
string(14) "genengnews.com"
["publication_date"]=>
string(10) "2023-03-31"
["categories"]=>
array(2) {
[0]=>
string(13) "Data Security"
[1]=>
string(12) "Stock Market"
}
}
[5]=>
array(7) {
["title_en"]=>
string(89) "Sanofi and Regeneron Report Positive COPD Data, Raising Dupixent’s Peak Sales Potential"
["snippet_en"]=>
string(168) "Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today."
["url"]=>
string(130) "https://www.morningstar.com/articles/1145795/sanofi-and-regeneron-report-positive-copd-data-raising-dupixents-peak-sales-potential"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/0a152936-606b-4196-96eb-d86233553c13"
["source"]=>
string(15) "morningstar.com"
["publication_date"]=>
string(10) "2023-03-24"
["categories"]=>
array(3) {
[0]=>
string(18) "General Investment"
[1]=>
string(13) "Data Security"
[2]=>
string(24) "Quarterly/Annual Figures"
}
}
[6]=>
array(7) {
["title_en"]=>
string(101) "Rancho Biosciences Welcomes Regeneron as the Newest Member to Its Single Cell Data Science Consortium"
["snippet_en"]=>
string(297) "The mission of the SCDS consortium is to find a common industry standard around how single cell datasets are created and formatted by a systematic effort to develop data models and ensure that public data are curated in a consistent way. Due to the undeniable impact of single cell transcriptomics"
["url"]=>
string(142) "https://www.dallassun.com/news/273653637/rancho-biosciences-welcomes-regeneron-as-the-newest-member-to-its-single-cell-data-science-consortium"
["image_url"]=>
NULL
["source"]=>
string(13) "dallassun.com"
["publication_date"]=>
string(10) "2023-03-21"
["categories"]=>
array(1) {
[0]=>
string(13) "Data Security"
}
}
[7]=>
array(7) {
["title_en"]=>
string(32) "A new paradigm for managing data"
["snippet_en"]=>
string(299) "Regeneron Pharmaceuticals, a biotechnology company that develops life-transforming medicines, found itself inundated with vast volumes of data during the peak of the covid-19 pandemic. In order to derive actionable information from these disparate data sets, which ranged from clinical trial data to"
["url"]=>
string(58) "https://whatsnew2day.com/a-new-paradigm-for-managing-data/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/86c1db7b-9670-42e8-8c3f-14c3336911b9"
["source"]=>
string(16) "whatsnew2day.com"
["publication_date"]=>
string(10) "2023-03-17"
["categories"]=>
array(4) {
[0]=>
string(8) "Epidemic"
[1]=>
string(13) "Data Security"
[2]=>
string(10) "Cybercrime"
[3]=>
string(16) "Customer Privacy"
}
}
[8]=>
array(7) {
["title_en"]=>
string(45) "Regeneron and GSK to sequence UK genetic data"
["snippet_en"]=>
string(45) "Regeneron and GSK to sequence UK genetic data"
["url"]=>
string(78) "https://pharmaphorum.com/index.php/news/regeneron-gsk-sequence-uk-genetic-data"
["image_url"]=>
NULL
["source"]=>
string(16) "pharmaphorum.com"
["publication_date"]=>
string(10) "2023-02-07"
["categories"]=>
array(2) {
[0]=>
string(13) "Data Security"
[1]=>
string(10) "Cybercrime"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(99)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[22]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(28)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2432 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy.
ORLANDO – Regeneron on Monday revealed the data behind one of its BCMA and CD3-directed bispecific antibodies that it has decided not to take forward for multiple myeloma.
Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.
The mission of the SCDS consortium is to find a common industry standard around how single cell datasets are created and formatted by a systematic effort to develop data models and ensure that public data are curated in a consistent way. Due to the undeniable impact of single cell transcriptomics
Regeneron Pharmaceuticals, a biotechnology company that develops life-transforming medicines, found itself inundated with vast volumes of data during the peak of the covid-19 pandemic. In order to derive actionable information from these disparate data sets, which ranged from clinical trial data to
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
